Business
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countries CRANFORD, N.J., Oct. 7, 2025
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"\n Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countries\n \n \n CRANFORD, N.J., Oct. 7, 2025 /PRNewswire/ -- Citius Oncology, Inc. (\"Citius Oncology\" or the \"Company\") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies today announced it is actively engaging with regional distribution partners to make LYMPHIR™ (denileukin diftitox-cxdl) available to eligible patients through country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East. As part of its NPP strategy, Citius has entered into an exclusive distribution agreement with Integris Pharma S.A., headquartered in Athens, Greece. The partnership covers Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia.\n \n \n \n \n \n \n \n Named Patient Programs, also known as early access programs, are formally recognized pathways designed to give patients earlier access to promising new medicines in advance of full marketing authorization and commercial availability in markets outside the United States. Under these programs, a treating physician may request a therapy on behalf of an individual patient when no adequate approved alternatives exist. In doing so, NPPs bridge a critical gap between the completion of clinical trials in each region and broad market introduction, ensuring that patients with serious illnesses are not left waiting for life-extending innovations. These programs provide access, where permitted by local law, and do not constitute commercial approval of LYMPHIR outside the United States.\n \"As we prepare to launch LYMPHIR in the U.S., expanding access to international markets through Named Patient Programs is both a patient-driven mission and a strategic opportunity for Citius Oncology. These programs allow us to serve patients who urgently need new treatment options, while also giving physicians valuable firsthand experience with LYMPHIR. Our recently signed exclusive distribution agreement with Integris Pharma S.A. further strengthens this effort, establishing a trusted partner to help us bring LYMPHIR to patients across Southern Europe and the Balkans. By accessing NPP pathways outside the U.S., w...